can you take semaglutide with crohn's disease GLP-1 Use in Disease: Safety & IBD Considerations – PlexusDx GLP-1 and Crohn's Disease: Safety

Nat Rev Cardiol 23 , 449451 (2026)

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist, while Tirzepatide (Mounjaro, Zepbound) binds with both receptors (GLP-1 and GIP) and thus tends to have more effects on weight loss than semaglutide alone

These impacts are especially noticeable in the first four to eight weeks of a patients GLP-1 weight loss journey, leading to issues like constipation, nausea, bloating, vomiting, and other gastrointestinal discomforts

doi: 10.1007/s00774-011-0321-5

Food and Drug Administration has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening, kidney failure, and death due to cardiovascular disease for adults living with type 2 diabetes and chronic kidney disease